

If a conflict arises between a Clinical Payment and Coding Policy and any plan document under which a member is entitled to Covered Services, the plan document will govern. If a conflict arises between a CPCP and any provider contract pursuant to which a provider participates in and/or provides Covered Services to eligible member(s) and/or plans, the provider contract will govern. "Plan documents" include, but are not limited to, Certificates of Health Care Benefits, benefit booklets, Summary Plan Descriptions, and other coverage documents. Blue Cross and Blue Shield of Texas may use reasonable discretion interpreting and applying this policy to services being delivered in a particular case. BCBSTX has full and final discretionary authority for their interpretation and application to the extent provided under any applicable plan documents.

Providers are responsible for submission of accurate documentation of services performed. Providers are expected to submit claims for services rendered using valid code combinations from Health Insurance Portability and Accountability Act approved code sets. Claims should be coded appropriately according to industry standard coding guidelines including, but not limited to: Uniform Billing Editor, American Medical Association, Current Procedural Terminology, CPT® Assistant, Healthcare Common Procedure Coding System, ICD-10 CM and PCS, National Drug Codes, Diagnosis Related Group guidelines, Centers for Medicare and Medicaid Services National Correct Coding Initiative Policy Manual, CCI table edits and other CMS guidelines.

Claims are subject to the code edit protocols for services/procedures billed. Claim submissions are subject to claim review including but not limited to, any terms of benefit coverage, provider contract language, medical policies, clinical payment and coding policies as well as coding software logic. Upon request, the provider is urged to submit any additional documentation.

Oral Cancer Screening and Testing

Policy Number: CPCPLAB032

Version 1.0

Approval Date: February 5, 2025

Plan Effective Date: May 15, 2025

Description

The plan has implemented certain lab management reimbursement criteria. Not all

requirements apply to each product. Providers are urged to review Plan documents for eligible coverage for services rendered.

Reimbursement Information:

1. To establish HPV tumor status for individuals with oropharyngeal squamous cell carcinoma, testing for high-risk HPV testing with either mRNA expression testing for HPV E6/E7 or immunohistochemistry **may be reimbursable**.
2. To screen, detect, or diagnose oral cancer, the following testing **is not reimbursable**:
 - a. Salivary biomarker testing (e.g., peptides/proteins, nucleic acids, metabolites).
 - b. Panels that incorporate genetic risk factors with nongenetic biomarkers (e.g., mRNA CancerDetect™).

Procedure Codes

The following is not an all-encompassing code list. The inclusion of a code does not guarantee it is a covered service or eligible for reimbursement.

Codes
81599, 82397, 87624, 87625, 87626, 88341, 88342, 0296U, 0429U

References:

- ACS. (2024). *Key Statistics for Oral Cavity and Oropharyngeal Cancers*.
<https://www.cancer.org/cancer/oral-cavity-and-oropharyngeal-cancer/about/key-statistics.html>
- Alsarraf, A. H., Kujan, O., & Farah, C. S. (2018). The utility of oral brush cytology in the early detection of oral cancer and oral potentially malignant disorders: A systematic review. *J Oral Pathol Med*, 47(2), 104-116.
<https://doi.org/10.1111/jop.12660>
- Borsetto, D., Cheng, J., Payne, K., Nankivell, P., Batis, N., Rao, K., Bhide, S., Li, F., Kim, Y., Mehanna, H., & Wong, D. (2018). Surveillance of HPV-Positive Head and Neck Squamous Cell Carcinoma with Circulating and Salivary DNA Biomarkers. *Crit Rev Oncog*, 23(3-4), 235-245. <https://doi.org/10.1615/CritRevOncog.2018027689>
- Brocklehurst, P., Kujan, O., O'Malley, L., Ogden, G. R., Shepherd, S., & Glenny, A. M. (2013). Screening programmes for the early detection and prevention of oral cancer. *Cochrane Database of Systematic Reviews*(11).
<https://doi.org/10.1002/14651858.CD004150.pub4>

- CDC. (2024, 02/06/2024). *About Genital HPV Infection*.
<https://www.cdc.gov/sti/about/about-genital-hpv-infection.html>
- Dhanuthai, K., Rojanawatsirivej, S., Thosaporn, W., Kintarak, S., Subarnbhesaj, A., Darling, M., Kryshtalskyj, E., Chiang, C. P., Shin, H. I., Choi, S. Y., Lee, S. S., & Aminishakib, P. (2018). Oral cancer: A multicenter study. *Medicina oral, patologia oral y cirugia bucal*, 23(1), e23-e29. <https://doi.org/10.4317/medoral.21999>
- Fakhry, C., Lacchetti, C., Rooper, L. M., Jordan, R. C., Rischin, D., Sturgis, E. M., Bell, D., Lingen, M. W., Harichand-Herdt, S., Thibo, J., Zevallos, J., & Perez-Ordóñez, B. (2018). Human Papillomavirus Testing in Head and Neck Carcinomas: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists Guideline. *J Clin Oncol*, 36(31), 3152-3161. <https://doi.org/10.1200/jco.18.00684>
- Fedele, S. (2009). Diagnostic aids in the screening of oral cancer. *Head Neck Oncol*, 1, 5. <https://doi.org/10.1186/1758-3284-1-5>
- Gross, N., Lee, N., Okuno, S., & Rao, S. (2024, Feb 1 2024). *Treatment of stage I and II (early) head and neck cancer: The oral cavity*.
<https://www.uptodate.com/contents/treatment-of-stage-i-and-ii-early-head-and-neck-cancer-the-oral-cavity>
- Jain, A., Kotimoole, C. N., Ghoshal, S., Bakshi, J., Chatterjee, A., Prasad, T. S. K., & Pal, A. (2021). Identification of potential salivary biomarker panels for oral squamous cell carcinoma. *Scientific Reports*, 11(1), 3365. <https://doi.org/10.1038/s41598-021-82635-0>
- Kaur, J., Jacobs, R., Huang, Y., Salvo, N., & Politis, C. (2018). Salivary biomarkers for oral cancer and pre-cancer screening: a review. *Clin Oral Investig*, 22(2), 633-640. <https://doi.org/10.1007/s00784-018-2337-x>
- Lewis, J. S., Jr., Beadle, B., Bishop, J. A., Chernock, R. D., Colasacco, C., Lacchetti, C., Moncur, J. T., Rocco, J. W., Schwartz, M. R., Seethala, R. R., Thomas, N. E., Westra, W. H., & Faquin, W. C. (2018). Human Papillomavirus Testing in Head and Neck Carcinomas: Guideline From the College of American Pathologists. *Arch Pathol Lab Med*, 142(5), 559-597. <https://doi.org/10.5858/arpa.2017-0286-CP>
- Lim, Y., Wan, Y., Vagenas, D., Ovchinnikov, D. A., Perry, C. F., Davis, M. J., & Punyadeera, C. (2016). Salivary DNA methylation panel to diagnose HPV-positive and HPV-negative head and neck cancers. *BMC Cancer*, 16(1), 749. <https://doi.org/10.1186/s12885-016-2785-0>
- Lingen, M. W., Abt, E., Agrawal, N., Chaturvedi, A. K., Cohen, E., D'Souza, G., Gurenlian, J., Kalmar, J. R., Kerr, A. R., Lambert, P. M., Patton, L. L., Sollecito, T. P., Truelove, E., Tampi, M. P., Urquhart, O., Banfield, L., & Carrasco-Labra, A. (2017). Evidence-based clinical practice guideline for the evaluation of potentially malignant disorders in the oral cavity: A report of the American Dental Association. *The Journal of the American Dental Association*, 148(10), 712-727.e710. <https://doi.org/10.1016/j.adaj.2017.07.032>
- Lingen, M. W., Kalmar, J. R., Karrison, T., & Speight, P. M. (2008). Critical evaluation of diagnostic aids for the detection of oral cancer. *Oral Oncol*, 44(1), 10-22. <https://doi.org/10.1016/j.oraloncology.2007.06.011>

- Liyanage, C., Wathupola, A., Muraleetharan, S., Perera, K., Punyadeera, C., & Udagama, P. (2019). Promoter Hypermethylation of Tumor-Suppressor Genes p16(INK4a), RASSF1A, TIMP3, and PCQAP/MED15 in Salivary DNA as a Quadruple Biomarker Panel for Early Detection of Oral and Oropharyngeal Cancers. *Biomolecules*, 9(4). <https://doi.org/10.3390/biom9040148>
- Lodi, G. (2024, April 1, 2024). *Oral Lesions*. <https://www.uptodate.com/contents/oral-lesions>
- Macey, R., Walsh, T., Brocklehurst, P., Kerr, A. R., Liu, J. L., Lingen, M. W., Ogden, G. R., Warnakulasuriya, S., & Scully, C. (2015). Diagnostic tests for oral cancer and potentially malignant disorders in patients presenting with clinically evident lesions. *Cochrane Database Syst Rev*(5), Cd010276. <https://doi.org/10.1002/14651858.CD010276.pub2>
- Machiels, J. P., René Leemans, C., Golusinski, W., Grau, C., Licitra, L., & Gregoire, V. (2020). Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*, 31(11), 1462-1475. <https://doi.org/10.1016/j.annonc.2020.07.011>
- Maghami, E., Ismaila, N., Alvarez, A., Chernock, R., Duvvuri, U., Geiger, J., Gross, N., Haughey, B., Paul, D., Rodriguez, C., Sher, D., Stambuk, H. E., Waldron, J., Witek, M., & Caudell, J. (2020). Diagnosis and Management of Squamous Cell Carcinoma of Unknown Primary in the Head and Neck: ASCO Guideline. *J Clin Oncol*, 38(22), 2570-2596. <https://doi.org/10.1200/jco.20.00275>
- Mascitti, M., Orsini, G., Tosco, V., Monterubbianesi, R., Balercia, A., Putignano, A., Procaccini, M., & Santarelli, A. (2018). An Overview on Current Non-invasive Diagnostic Devices in Oral Oncology. *Frontiers in physiology*, 9, 1510-1510. <https://doi.org/10.3389/fphys.2018.01510>
- Moyer, V. A. o. b. o. t., U. S. Preventive Services Task Force. (2014). Screening for Oral Cancer: U.S. Preventive Services Task Force Recommendation Statement. *Annals of Internal Medicine*, 160(1), 55-60. <https://doi.org/10.7326/M13-2568>
- Nagi, R., Reddy-Kantharaj, Y. B., Rakesh, N., Janardhan-Reddy, S., & Sahu, S. (2016). Efficacy of light based detection systems for early detection of oral cancer and oral potentially malignant disorders: Systematic review. *Medicina oral, patologia oral y cirugia bucal*, 21(4), e447-455. <https://doi.org/10.4317/medoral.21104>
- NCCN. (2024, May 1, 2024). *NCCN Clinical Practice Guidelines in Oncology - Head and Neck Cancers Version 4.2024*. https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf
- OralDNA. (2023). *OraRisk® HPV Complete Genotyping*. <https://www.oraldna.com/test/ohpv-complete/>
- Patton, L. L., Epstein, J. B., & Kerr, A. R. (2008). Adjunctive techniques for oral cancer examination and lesion diagnosis: a systematic review of the literature. *J Am Dent Assoc*, 139(7), 896-905; quiz 993-894. [https://jada.ada.org/article/S0002-8177\(14\)65381-2/fulltext](https://jada.ada.org/article/S0002-8177(14)65381-2/fulltext)
- Rethman, M. P., Carpenter, W., Cohen, E. E., Epstein, J., Evans, C. A., Flaitz, C. M., Graham, F. J., Hujoel, P. P., Kalmar, J. R., Koch, W. M., Lambert, P. M., Lingen, M.

W., Oettmeier, B. W., Jr., Patton, L. L., Perkins, D., Reid, B. C., Sciubba, J. J., Tomar, S. L., Wyatt, A. D., Jr., . . . Meyer, D. M. (2010). Evidence-based clinical recommendations regarding screening for oral squamous cell carcinomas. *J Am Dent Assoc*, 141(5), 509-520. <https://pubmed.ncbi.nlm.nih.gov/20436098/>

Ribeiro, I. P., Esteves, L., Santos, A., Barroso, L., Marques, F., Caramelo, F., Melo, J. B., & Carreira, I. M. (2021). A seven-gene signature to predict the prognosis of oral squamous cell carcinoma. *Oncogene*, 40(22), 3859-3869. <https://doi.org/10.1038/s41388-021-01806-5>

Scully, C., & Porter, S. (2000). ABC of oral health. Oral cancer. *Bmj*, 321(7253), 97-100. <https://pubmed.ncbi.nlm.nih.gov/10884263/>

Seoane Leston, J., & Diz Dios, P. (2010). Diagnostic clinical aids in oral cancer. *Oral Oncol*, 46(6), 418-422. <https://doi.org/10.1016/j.oraloncology.2010.03.006>

Siegel, R. L., Miller, K. D., & Jemal, A. (2019). Cancer statistics, 2019. *CA: A Cancer Journal for Clinicians*, 69(1), 7-34. <https://doi.org/10.3322/caac.21551>

Speight, P. M., Epstein, J., Kujan, O., Lingen, M. W., Nagao, T., Ranganathan, K., & Vargas, P. (2017). Screening for oral cancer-a perspective from the Global Oral Cancer Forum. *Oral Surg Oral Med Oral Pathol Oral Radiol*, 123(6), 680-687. <https://doi.org/10.1016/j.oooo.2016.08.021>

van der Waal, I. (2009). Potentially malignant disorders of the oral and oropharyngeal mucosa; terminology, classification and present concepts of management. *Oral Oncol*, 45(4-5), 317-323. <https://doi.org/10.1016/j.oraloncology.2008.05.016>

Warnakulasuriya, S., Johnson, N. W., & van der Waal, I. (2007). Nomenclature and classification of potentially malignant disorders of the oral mucosa. *J Oral Pathol Med*, 36(10), 575-580. <https://doi.org/10.1111/j.1600-0714.2007.00582.x>

Policy Update History:

Approval Date	Effective Date; Summary of Changes
02/05/2025	05/15/2025; Document updated with literature review. The following change was made to Reimbursement Information: Revised #1 for intent of test; added "To establish HPV tumor status..." Added #2: To screen, detect, or diagnose oral cancer, the following testing is not reimbursable: a. Salivary biomarker testing (e.g., peptides/proteins, nucleic acids, metabolites). b. Panels that incorporate genetic risk factors with nongenetic biomarkers (e.g., mRNA CancerDetect™). Added codes 87626, 0429U; removed code 87623. References revised.
09/13/2024	01/01/2025: New policy.